Innovators of Circadian PhotoDynamic
NeuroEndocrine Resetting Therapy (PDT)
“Our company is dedicated to understanding and applying nature’s genius to successfully treat human disease and thereby improve the human condition”
President and Chief Science Officer
VeroScience is a biotechnology company focused on the development of therapies and products to improve human health. The company has a strong pipeline of metabolic disease products and therapies for immunological disorders.
VeroScience is a hybrid of academic environment mindset and industrial focus within a small and efficient organization. The company conducts preclinical and clinical research nation-wide, utilizing strong academic and pharmaceutical industry collaborations to advance its development programs.
A major platform technology of the company is Circadian Neuroendocrine Resetting Therapy® that is utilized as a generator of multiple therapeutic strategies to treat a variety of disease states. The circadian timed daily (morning) administration of Cycloset®, a quick release formulation of bromocriptine mesylate, a dopamine agonist, was developed for the treatment of type 2 diabetes. Cycloset is approved by the U.S. FDA, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Creators of Cycloset, the first
and only FDA approved
centrally acting dopamine
agonist oral antidiabetic